drugset / Trial / NCT07558733
Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The study is a Phase 1b/2, multi-center, open-label, dose escalation trial evaluating the safety and preliminary efficacy of sapanisertib and serabelisib (PIKTOR) with fulvestrant and/or other anticancer therapies in participants with HR+/HER2- advanced/metastatic breast cancer.
Timeline
- Start
- 2026-04-22
- Primary completion
- 2029-05
- Completion
- 2033-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sapanisertib | Small molecule | — | Oral |
| Subject | Serabelisib | Small molecule | — | Oral |
| Background | Fulvestrant | Small molecule | — | Intramuscular |